Factors Affecting Immunoreactive Thromboxane B2 in Kidney Transplant Patients
Immune responses involve activation of blood elements such as lymphocytes, granulocytes, monocytes, and platelets. Activation of these cells entail formation of thromboxane A2 TXA2 and other metabolites of arachidonic acid. 1–5 The site of the immunological response in renal transplantation is the allograft. Consequently, the arachidonate products are also likely to be of renal origin and may be reflected in the urine. Thus the monitoring of urine for thromboxane, leukotrienes, and prostaglandins may reflect the immunological reaction. Moreover, since the early events in cell activation involve arachidonate release and metabolism, these products should provide an early indicator of increased activation. Recently we have observed increased urinary thromboxane B2 concentrations during human kidney allograft rejection.6
KeywordsDeep Venous Thrombosis Allograft Rejection Rejection Episode Acute Tubular Necrosis Human Peripheral Blood Mononuclear Cell
Unable to display preview. Download preview PDF.
- 4.Kennedy MS, Stobo JD, Goldyne ME: In vitro synthesis of prostaglandins and related lipids by populations of human peripheral blood mononuclear cells. Prostaglandins 20: 135–145, 1979.Google Scholar
- 9.Fitzgerald GA, Maas RL, Lawson JA, Roberts LF, and Brash AR: Aspirin inhibits edogenous prostacyclin and thromboxane synthesis in man, in: Samuelsson B, Ramwell P, and Paoletti R (eds): Adv. Prostaglandins, Thromboxane, and Leukotrienes, Vol. 11, New York, Raven Press, 1982.Google Scholar
- 10.Kawana S, Katori M: Personal communication.Google Scholar
- 12.Schwarz M, Leithner C, Sinzinger H: Platelet deposition in renal transplant rejection and treatment with prostacyclin infusion. (This symposium)Google Scholar